Five glycomics projects have been awarded funding to develop new tools, diagnostics and therapeutics to improve health for Canadians. EDMONTON, AB — GlycoNet, one of the global leaders in glycomics… Read More
Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough Currently in phase III clinical development with… Read More
ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles ZW171 induced potent preferential killing of cancer cells and potential to mitigate risk of… Read More
Routine pre-surgical use of nasal photodisinfection could prevent tens of thousands of surgical site infections a year in the US alone[i] VANCOUVER, BC — Ondine Biomedical Inc. (LON: OBI) presented… Read More
VANCOUVER, BC — Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim results from a Phase 2 clinical trial evaluating BOLD-100 in combination with standard-of-care chemotherapy… Read More
